

PRESS RELEASEAjinomoto Co., Inc.
15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JAPAN

Ajinomoto Group Completes Acquisition of Forge Biologics

TOKYO, December 22, 2023 – Today, Ajinomoto Co., Inc. (“Ajinomoto Co.”) announced that it completed procedures on December 21, 2023 (local time) for acquisition of all equities of Forge Biologics Holdings, LLC (“Forge”) through its consolidated subsidiary Ajinomoto North America Holdings, Inc., in line with its press release “Ajinomoto Group Acquires Forge Biologics, a US-Based Gene Therapy CDMO for Approximately JPY 82.8 Billion” dated November 13, 2023.

In the Medium-Term ASV Initiatives 2030 Roadmap announced in February this year, Ajinomoto Co. identified four strategic growth areas, including Healthcare, leveraging the strengths of its proprietary “AminoScience” platform. With the integration of the Ajinomoto Group’s “AminoScience” technology platform with Forge’s gene therapy CDMO platform through this acquisition, the Group aims to open new treatment paths for people suffering from rare diseases and achieve early realization of the Roadmap by building a strong business infrastructure in cutting-edge medical fields. Envisioning progress up to 2050, by entering next-generation business areas based on the technologies and customers cultivated up to now, it will promote transition to a high value-added business model leading to accelerated growth and higher profitability in the healthcare field.

1. Date of Acquisition

December 21, 2023 (U.S. local time).

2. Acquisition value

USD 545million (JPY 78.2billion). *1,2

3. Profile of Forge

- (1) Company name: Forge Biologics Holdings, LLC
- (2) Location: Grove City, Ohio, USA
- (3) Representative: Jiro Sakamoto
- (4) Business description: Gene therapy CDMO, gene therapy drug development

*1 USD 1 = JPY 143.48 (exchange rate at the time of share acquisition)

*2 As price adjustments will be made after the acquisition of equities, the acquisition value is not fixed at present.

Reference

Press release dated November 13, 2023:

Ajinomoto Group Acquires Forge Biologics, a US-Based Gene Therapy CDMO for Approximately JPY 82.8 Billion

https://www.ajinomoto.com/cms_wp_ajmnt_global/wp-content/uploads/pdf/2023_11_13E.pdf

This document is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements, under the United States Securities Act of 1933, as amended.

The Ajinomoto Group will contribute to the well-being of all human beings, our society and our planet with “AminoScience” based on the corporate slogan “Eat Well, Live Well.”. The Ajinomoto Group has offices in 36 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2022, sales were 1.3591 trillion yen (10.0 billion U.S. dollars). To learn more, visit www.ajinomoto.com.

For further information, please contact: [HERE](#)